AVE-1642 is under clinical development by Viridian Therapeutics and currently in Phase III for Graves’ Ophthalmopathy. According to GlobalData, Phase III drugs for Graves’ Ophthalmopathy have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AVE-1642’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVE-1642 overview
AVE-1642 is under development for Grave's ophthalmopathy (thyroid eye disease). AVE1642 is administered as an intravenous infusion route. AVE1642 is a humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) with potential antineoplastic activity. The drug candidate is developed by using proprietary TAP technology.
See Also:
It was under development for the treatment of recurrent, refractory multiple myeloma, advanced or metastatic liver carcinoma and advanced hormono-dependent breast cancer. It was also under development for subcutaneous route.
Viridian Therapeutics overview
Viridian Therapeutics (Viridian), formerly Miragen Therapeutics Inc is a clinical stage biopharmaceutical company. The company discovers and develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. It focuses on thyroid eye disease and cardiovascular disease areas. It’s lead pipeline products candidates include VRDN-001 (Intravenous) for treating thyroid eye disease (TED); and VRDN-002 (Subcutaneous), an inhibitor using half-life technology for treating thyroid eye disease (TED). The company has been depending on the third parties for the manufacturing and supply of the products. Viridian is headquartered in Boulder, Colorado, the US.
For a complete picture of AVE-1642’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
